EHA 2024 | An overview of bispecifics in R/R myeloma and their integration into the treatment landscape

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, provides an overview of the immunotherapy landscape in relapsed/refractory (R/R) multiple myeloma (MM), with a focus on bispecific antibodies. The anti-BCMA antibodies teclistamab and elranatamab result in a high overall response rate (ORR), with many of these responses being complete responses (CR) or very good partial responses (VGPR), which are rapidly achieved. Prof. Mohty also discusses the dosing schedules of these two agents in clinical practice. Talquetamab, a GPRC5D-targeted antibody, is associated with a greater incidence of side effects but can be used in patients who fail anti-BCMA antibody treatment. Along with other immunotherapeutic approaches, such as CAR T-cell products idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), these bispecific antibodies form a range of well-established treatments that have greatly improved the outcomes of patients with R/R myeloma. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.